Douglas K. Graham

6.6k total citations · 2 hit papers
128 papers, 4.7k citations indexed

About

Douglas K. Graham is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Douglas K. Graham has authored 128 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Immunology, 38 papers in Molecular Biology and 24 papers in Oncology. Recurrent topics in Douglas K. Graham's work include Phagocytosis and Immune Regulation (81 papers), Cancer Mechanisms and Therapy (14 papers) and Cell death mechanisms and regulation (12 papers). Douglas K. Graham is often cited by papers focused on Phagocytosis and Immune Regulation (81 papers), Cancer Mechanisms and Therapy (14 papers) and Cell death mechanisms and regulation (12 papers). Douglas K. Graham collaborates with scholars based in United States, Germany and Russia. Douglas K. Graham's co-authors include H. Shelton Earp, Deborah DeRyckere, Amy K. Keating, Rachel M.A. Linger, Kurtis D. Davies, Susan Sather, Xiayuan Liang, Xiaodong Wang, Christopher T. Cummings and Stephen V. Frye and has published in prestigious journals such as Journal of the American Chemical Society, Advanced Materials and Journal of Biological Chemistry.

In The Last Decade

Douglas K. Graham

117 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

TAM Receptor Tyrosine Kinases: Biologic Functions, Signaling, and Potential Therapeutic Targeting in Human Cancer

2008 577 citations Amy K. Keating, H. Shelton Earp et al. profile →
The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer

2014 548 citations Douglas K. Graham, Deborah DeRyckere et al. profile →

Peers

Douglas K. Graham

IMMUN

ONCOL

PHYSI

PFM

Hilary A. Kenny United States

Cheryl Nickerson‐Nutter United States

Pnina Brodt Canada

Robert D. Loberg United States

Sandra S. McAllister United States

Christina M. Annunziata United States

Kazuki Nakatani Japan

Stefania Scala Italy

Els M.E. Verdegaal Netherlands

Ian Spendlove United Kingdom

Hilary A. Kenny United States

Douglas K. Graham

1.1k ×0.3

IMMUN

2.6k ×1.9

1.8k ×1.8

ONCOL

277 ×0.5

PHYSI

214 ×0.4

PFM

Citations per year, relative to Douglas K. Graham Douglas K. Graham (= 1×) peers Hilary A. Kenny

Countries citing papers authored by Douglas K. Graham

Since Specialization

Citations

This map shows the geographic impact of Douglas K. Graham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas K. Graham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas K. Graham more than expected).

Fields of papers citing papers by Douglas K. Graham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas K. Graham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas K. Graham. The network helps show where Douglas K. Graham may publish in the future.

Co-authorship network of co-authors of Douglas K. Graham

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas K. Graham. A scholar is included among the top collaborators of Douglas K. Graham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas K. Graham. Douglas K. Graham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kong, Deyu, Jichen Zhao, Michael A. Stashko, et al.. (2025). Discovery of Novel TYRO3/MERTK Dual Inhibitors. Journal of Medicinal Chemistry. 68(8). 8455–8470.

Mumme, Hope, Sunil S. Raikar, Deborah DeRyckere, et al.. (2025). Identification of leukemia-enriched signature through the development of a comprehensive pediatric single-cell atlas. Nature Communications. 16(1). 4114–4114.

Mumme, Hope, Deborah DeRyckere, Kelly K. Ferguson, et al.. (2025). Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML. Leukemia. 39(11). 2721–2734.

Mumme, Hope, Beena Thomas, Swati S. Bhasin, et al.. (2023). Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia. Nature Communications. 14(1). 6209–6209. 38 indexed citations

Galat, Yekaterina, Yuchen Du, Xiao‐Nan Li, et al.. (2023). In vitro vascular differentiation system efficiently produces natural killer cells for cancer immunotherapies. OncoImmunology. 12(1). 2240670–2240670. 6 indexed citations

DeRyckere, Deborah, et al.. (2023). Abstract 4991: Phosphorylation of MERTK is required for nuclear localization in non-small cell lung cancer (NSCLC). Cancer Research. 83(7_Supplement). 4991–4991. 2 indexed citations

Wang, Xiaodong, H. Shelton Earp, Stephen V. Frye, et al.. (2023). Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment. Frontiers in Immunology. 14. 1146721–1146721. 15 indexed citations

Summers, Ryan J., Sharon M. Castellino, Christopher C. Porter, et al.. (2022). Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care. JCO Precision Oncology. 6(6). e2100451–e2100451. 8 indexed citations

Lee, Miyoung, Ganesh R. Talekar, Manali Rupji, et al.. (2022). Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia. Nature Communications. 13(1). 1157–1157. 25 indexed citations

10.

Thomas, Beena, Swati S. Bhasin, Debasree Sarkar, et al.. (2020). Single Cell Transcriptomics Revealed AML and Non-AML Cell Clusters Relevant to Relapse and Remission in Pediatric AML. Blood. 136(Supplement 1). 24–25. 6 indexed citations

11.

Holtzhausen, Alisha, Eric Ubil, Debra M. Hunter, et al.. (2019). TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti–PD-1 Therapy in Melanoma. Cancer Immunology Research. 7(10). 1672–1686. 98 indexed citations

12.

Yan, Dan, Rebecca E. Parker, Xiaodong Wang, et al.. (2018). MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non–small Cell Lung Cancers Expressing Wild-type EGFR Family Members. Clinical Cancer Research. 24(24). 6523–6535. 27 indexed citations

13.

Minson, Katherine A., John J. Tentler, Stacey M. Bagby, et al.. (2018). Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma. Molecular Cancer Therapeutics. 18(2). 278–288. 26 indexed citations

14.

Cummings, Christopher T., Mari Iida, Rebecca E. Parker, et al.. (2018). MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents. Molecular Cancer Therapeutics. 17(11). 2297–2308. 41 indexed citations

15.

Summers, Ryan J., Katherine A. Minson, Stephen V. Frye, et al.. (2017). Mertk Is a Therapeutic Target in Early T-Precursor Acute Lymphoblastic Leukemia. Blood. 130. 2536. 1 indexed citations

16.

DeRyckere, Deborah, Alisa B. Lee‐Sherick, Amanda A. Hill, et al.. (2016). UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models. Clinical Cancer Research. 23(6). 1481–1492. 51 indexed citations

17.

Cummings, Christopher T., Weihe Zhang, Kurtis D. Davies, et al.. (2015). Small Molecule Inhibition of MERTK Is Efficacious in Non–Small Cell Lung Cancer Models Independent of Driver Oncogene Status. Molecular Cancer Therapeutics. 14(9). 2014–2022. 50 indexed citations

18.

Alvarez‐Calderon, Francesca, Mark A. Gregory, Deborah DeRyckere, et al.. (2014). Tyrosine Kinase Inhibition in Leukemia Induces an Altered Metabolic State Sensitive to Mitochondrial Perturbations. Clinical Cancer Research. 21(6). 1360–1372. 56 indexed citations

19.

Rogers, Aaron, et al.. (2011). Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology. Oncogene. 31(38). 4171–4181. 52 indexed citations

20.

Keating, Amy K., Andrew M. Donson, Kathryn E. Ware, et al.. (2010). Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved Chemosensitivity. Molecular Cancer Therapeutics. 9(5). 1298–1307. 120 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact